Abstract

BackgroundRecurrence is a problem for many patients who have episodes of depression. In experimental settings, hyporeactivity in the Electrodermal Orienting Reactivity (EDOR) test has been observed to be more frequent in these patients. The aim of this study was to investigate the clinical value of this test with regard to a prognosis of episode recurrence in patients hospitalized for depression.MethodsThe study was performed using a cohort design at a specialized psychiatric clinic in Warsaw, Poland. The primary endpoint measure was relapse or recurrence of depression. Data on electrodermal reactivity measured by the EDOR test, clinical status, and psychiatric history were collected at the clinic. Relapse and recurrence data were collected by clinical interviews 1 year after the EDOR test. The predictive (adjusting for confounders) and comparative (relative to other predictors) performance of electrodermal hyporeactivity was assessed using simple and multiple binary logistic regression.ResultsThe patient sample included 97 patients aged between 20 and 81 years (mean, 51.2 years). Twenty patients (20.6%) were hyporeactive in the EDOR test. The group of hyporeactive patients did not differ significantly from the reactive group with regard to background factors or clinical status on admission. Forty-seven patients (51.6%) had at least one depressive episode during the follow-up period. In the analysis including potential confounders, the likelihood of relapse or recurrence of depression was nearly five times higher among the hyporeactive patients than the reactive patients (odds ratio [OR], 4.7; 95% confidence interval (CI), 1.3–16.2; p = 0.015). In the comparative analysis, only hyporeactivity was found to be associated with recurring episodes (OR, 3.3; 95% CI, 1.1–10.2; p = 0.036).ConclusionsElectrodermal hyporeactivity was associated with a higher risk of relapse or recurrence after discharge among patients hospitalized for depression. This finding warrants further clinical investigations that cover different types of depression and account for causal mechanisms.Trial registrationThe study design was registered in the German Clinical Trials Register (DRKS00010082).

Highlights

  • Depression is an increasingly prevalent psychiatric disorder that constitutes a significant burden on health care systems worldwide [1]

  • Eight patients were excluded from the analysis because of technical problems (EDOR test interrupted or not recorded properly, test result invalid) or because of a change in the diagnosis during hospitalization

  • According to the ICD-10 classification, 61 patients in the final sample were diagnosed with bipolar disorder, 21 with recurrent depressive disorder, and 15 with a depressive episode

Read more

Summary

Introduction

Depression is an increasingly prevalent psychiatric disorder that constitutes a significant burden on health care systems worldwide [1]. 40 to 60% of patients with a first-time episode of major depression develop a subsequent episode [3], and the risk increases further with each new episode [4]. This implies that there is a need for knowledge about reliable determinants of a “relapsing-remitting” course of the disorder [5]. Dysregulation of the ANS is a recognized diagnostic characteristic of depression, with symptoms such as loss of energy, weight loss/gain, and sleep disturbances [9]. The aim of this study was to investigate the clinical value of this test with regard to a prognosis of episode recurrence in patients hospitalized for depression

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call